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Abstract: 
Aim 
Repetitive transcranial magnetic stimulation may have anti-epileptic effects, especially in neocortical epilepsy. 
Continuous thetaburst stimulation (cTBS) seems to be a potent protocol that could optimize safety, tolerability 
and applicability based on lower stimulation intensity and shorter duration. 
Methods 
Patients with refractory neocortical epilepsy are treated with a 4-day cTBS protocol (figure 1) targeted over the 
epileptogenic focus. Seizure frequency and adverse events are assessed over a 4-week baseline period and 8 
weeks of follow-up. Cognitive and psychological testing is performed at baseline and end of follow-up. 
Results 
Subject 1 and subject 2 suffer from epilepsy due to a low-grade tumor in the motor cortex causing focal clonic 
seizures. Subject 1 also experiences myoclonia of the left leg. Subject 3 has epilepsy with auditory seizures 
following intracranial hemorrhage in the left temporal lobe. 
cTBS was well-tolerated and did not induce serious adverse events or seizures. Mild headache occurred in 
subject 3. No negative cognitive or psychological side effects were noticed. 
Anti-epileptic effects of cTBS varied (figure 2). Subject 1 experienced a transient reduction in severity of clonic 
seizures, with complete resolution of myoclonia for 6 weeks. Subject 2 experienced an overall 50% seizure 
frequency reduction, with most pronounced effect during treatment and initial 4 weeks of follow-up (70% 
reduction, 3 seizure-free weeks). No marked effect on seizures was identified in subject 3. 
Conclusions 
cTBS appears safe and well-tolerated, even in seizure-prone subjects. Anti-epileptic effects of variable extent 
were identified. Extensive parenchymal damage at the target site may have interfered with effective 
stimulation in subject 3. 
